Dajun Yang

6PUBLICATIONS

61CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsBiomolecular modelling and design

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|May 09, 2026

Effects of a High-Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia.

|Sep 04, 2024

Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers.

Hengbang Wang, Yun Yang, Zi Chen

|Nov 16, 2023

First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.

Nehal J Lakhani, Drew Rasco, Hengbang Wang

|Apr 19, 2023

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.

Sikander Ailawadhi, Zi Chen, Bo Huang

|Oct 14, 2022

Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.

Yifan Zhai, Qiuqiong Tang, Douglas D Fang

|Sep 01, 2022

Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.

Jing Deng, Aneel Paulus, Douglas D Fang

Pageof 1

Frequent Collaborators

Yifan Zhai

Hengbang Wang

Lichuang Men

Tommy Fu

Zi Chen

Yan Yin

Aneel Paulus

Douglas D Fang

Asher Chanan-Khan

Ping Min

Frequent Collaborators

Yifan Zhai

Hengbang Wang

Lichuang Men

Tommy Fu